Nektar Therapeutics (NKTR) Debt Components
- 2020-12-31: Senior Notes, CurrentUSD $0.00; Senior NotesUSD (m); Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2020-09-30: Senior Notes, CurrentUSD $0.00; Senior NotesUSD (m); Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2020-06-30: Senior Notes, CurrentUSD $0.00; Senior NotesUSD (m); Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2020-03-31: Senior Notes, CurrentUSD $254.14M; Senior NotesUSD $254.80M; Long-term DebtUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
Nektar Therapeutics Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Senior Notes, Current USD | Senior Notes USD | Long-term Debt USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Convertible, Conversion Ratio (Deprecated 2013-01-31) pure | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $254.14M | $254.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $252.89M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $250.00M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $125.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $133.50M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $134.80M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | 12.00% | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | 12.00% | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | 12.00% | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | 12.00% | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | 12.00% | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $2.40M |
| 2012-07-11 | (m) | $125.00M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $2.40M |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | 12 month · 4647.27% | (m) |
| 2011-12-31 | (m) | (m) | (m) | 3.25% | 21.52 | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $2.40M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |